Rhythm (United states)
RYTM
$92.31
+7.86%
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. It is a leader in developing melanocortin-4 receptor (MC4R) agonists as precision medicines for severe obesity caused by rare genetic disorders.
RYTM
Rhythm (United states)
$92.31
Related headlines
Investment Opinion: Should I buy RYTM Today?
Based on a synthesis of the data, the objective assessment is a Hold rating for risk-averse investors and a Speculative Buy only for those with a very high risk tolerance and long-term horizon. The company's strong commercial growth and analyst support are positive, but they are overwhelmingly offset by the combination of deep losses, a recent clinical failure, and a valuation that demands flawless future execution. The stock is not suitable for conservative portfolios.
Sign up to view all
RYTM 12-Month Price Forecast
The analysis yields a neutral stance due to powerful opposing forces: compelling growth and analyst conviction versus untenable losses, a clinical setback, and extreme valuation. The high probability base case reflects a challenging path for significant share price appreciation in the near term.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rhythm (United states)'s 12-month outlook, with a consensus price target around $120.00 and implied upside of +30.0% versus the current price.
Average Target
$120.00
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$74 - $120
Analyst target range
Wall Street maintains a bullish consensus on Rhythm Pharmaceuticals, with recent analyst actions uniformly positive. In March 2026, firms including Citigroup, B of A Securities, Morgan Stanley, RBC Capital, and HC Wainwright & Co. reiterated Buy, Overweight, or Outperform ratings. This suggests continued analyst confidence in the company's long-term strategy despite recent clinical setbacks. However, specific consensus price targets and ratings distribution data were not available in the provided inputs.
Bulls vs Bears: RYTM Investment Factors
RYTM presents a classic high-risk, high-reward biotech profile. Bullish drivers include robust revenue growth, a premium gross margin, and strong analyst support for its niche rare disease focus. However, these are counterbalanced by deep unprofitability, a sky-high valuation reliant on future success, and a recent significant clinical disappointment that has driven the stock's sharp decline.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 36.87% YoY, showing commercial traction.
- High Gross Margin: Gross margin of 89.73% indicates a profitable core product.
- Analyst Confidence: Multiple firms reiterated Buy/Overweight ratings in March 2026.
- Leadership in Niche Market: Focus on rare MC4R pathway diseases creates a defensible moat.
Bearish
- Persistent Heavy Losses: Net margin of -103.57% and negative free cash flow of $116.6M TTM.
- Extreme Valuation: PS ratio of 36.66 prices in near-perfect future execution.
- Recent Clinical Setback: Failed primary endpoint in key trial, per March 2026 news.
- High Financial Leverage: Debt-to-equity ratio of 1.77 indicates significant balance sheet risk.
RYTM Technical Analysis
The stock has experienced significant volatility and a pronounced downtrend over the observed period. From a high near $118 in mid-December 2025, the price has fallen to $86.97 as of March 31, 2026, representing a decline of over 26% from that peak. The price action shows a clear pattern of lower highs and lower lows since the start of 2026, indicating strong selling pressure.
Short-term performance has been weak. The stock declined 6.21% over the past month and 18.75% over the past three months, significantly underperforming the broader market (SPY) which fell 5.25% and 4.63% over the same periods, respectively. The sharp drop from $113.76 on October 31, 2025, to the current price highlights the sustained negative momentum.
The current price of $86.97 sits well below the 52-week high of $122.20 but remains significantly above the 52-week low of $45.905. This positions the stock in the upper half of its annual range, though the recent breakdown suggests it is testing lower support levels. No RSI data was provided for the current analysis.
Beta
1.94
1.94x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$55-$122
Price range past year
Annual Return
+43.3%
Cumulative gain past year
| Period | RYTM Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | +10.4% |
| 3m | -14.5% | +5.5% |
| 6m | -6.3% | +8.0% |
| 1y | +43.3% | +28.4% |
| ytd | -12.1% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RYTM Fundamental Analysis
Revenue growth has been strong on a year-over-year basis, with Q4 2025 revenue of $57.3 million representing a 36.87% increase from the same quarter a year prior. However, the company remains deeply unprofitable, with a net loss of $47.5 million in Q4 2025 and a negative net margin of -103.57%. Gross margins are exceptionally high at 89.73%, but these are overwhelmed by substantial operating expenses, primarily in research and development.
Financial health shows a mixed picture. The company has a high debt-to-equity ratio of 1.77, indicating significant leverage. Conversely, it maintains a strong current ratio of 4.41, suggesting good short-term liquidity. Cash flow is a major concern, with negative free cash flow of $116.6 million over the trailing twelve months and negative operating cash flow.
Operational efficiency metrics reflect the challenges of a pre-profitability biotech. Return on Equity (ROE) is deeply negative at -141.3%, and Return on Assets (ROA) is -27.51%, indicating the company is burning capital to fund operations and growth. Asset turnover is low, which is typical for a capital-intensive, research-driven firm.
Quarterly Revenue
$57253000.0B
2025-12
Revenue YoY Growth
+0.36%
YoY Comparison
Gross Margin
+0.91%
Latest Quarter
Free Cash Flow
$-116628000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RYTM Overvalued?
Given the company's consistent net losses and negative EBITDA, the Price-to-Sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 36.66, based on a market cap of approximately $6.96 billion. This is an extremely high multiple, reflecting investor expectations for significant future revenue growth and eventual profitability from its rare disease pipeline.
Peer comparison data for the biotechnology industry was not provided in the valuation inputs. Therefore, a relative assessment against industry averages cannot be made. The high PS ratio suggests the stock is priced for near-perfect execution and commercial success of its lead drug, IMCIVREE, and its pipeline candidates.
PE
-35.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -38x~6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-41.1x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is clinical and regulatory. The recent news of a failed trial for a rare obesity drug is a direct hit to the pipeline's value and forces a strategic pivot, increasing uncertainty. Financial risk is also high; the company is burning substantial cash ($116.6M TTM) with no clear path to profitability, supported by a leveraged balance sheet (Debt/Equity: 1.77). While liquidity is currently strong (Current Ratio: 4.41), the cash burn rate necessitates future capital raises, which could be dilutive. Market risk is pronounced, evidenced by the stock's high beta of 2.15, meaning it is more than twice as volatile as the market, and its severe recent underperformance during a broader market decline. The extreme Price-to-Sales multiple of 36.66 leaves the stock vulnerable to any disappointment in growth expectations or a sector-wide de-rating of biotech valuations.
FAQ
The key risks are: 1) Clinical/Regulatory: Recent trial failure for an obesity drug highlights pipeline risk. 2) Financial: The company is burning cash heavily (negative FCF of $116.6M TTM) with a high debt load (D/E of 1.77). 3) Valuation: The extreme PS ratio of 36.66 makes the stock vulnerable to de-rating. 4) Market: High beta of 2.15 means extreme volatility and underperformance in weak markets, as seen recently.
The 12-month outlook is highly uncertain. A base case (50% probability) sees the stock trading between $75 and $95, as growth continues but valuation caps gains. A bull case (25%) could see a rally to $110-$122 on pipeline success. A bear case (25%) risks a fall towards the 52-week low of $46 on further setbacks. The consensus is clouded by the recent clinical disappointment despite analyst Buy ratings.
Based on conventional metrics, RYTM appears significantly overvalued. With a Price-to-Sales ratio of 36.66 and no profits (negative PE), the stock is priced for nearly perfect future growth and pipeline success. This valuation is difficult to justify given the recent clinical setback and ongoing substantial cash burn. It is a premium valuation reflecting high hopes, not current fundamentals.
RYTM is a highly speculative stock, not a 'good buy' for most investors. While revenue is growing strongly (36.9% YoY) and analysts are bullish, the company is deeply unprofitable (net margin -103.6%), recently failed a key clinical trial, and trades at an extreme valuation (PS ratio 36.66). It is only suitable for investors with a very high risk tolerance and a long-term horizon who are betting on pipeline success.
RYTM is strictly a long-term investment for those who can wait 3-5 years for the pipeline to mature and (hopefully) reach profitability. It is entirely unsuitable for short-term trading due to its high volatility (beta 2.15), binary clinical news flow, and lack of earnings to support the price. The investment thesis hinges on long-term commercial execution and R&D success.